Vetter Grants Award for Novel Idea at the Open Innovation Challenge – Injection 2.0

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005504/en/

Vetter management representatives including Managing Director Thomas Otto (second from right), jury members Eva-Maria Markutzik (EIT Health Germany, first right) and Prof. Dr. med. habil. Folker Wenzel (HFU Furtwangen, fifth from right) congratulate the members of the winning team at the symbolic check hand-over. Picture source: Vetter Pharma International GmbH

The four teams were arranged in a multidisciplinary fashion, including students and professionals from the fields of medicine and economic sciences, as well as members of the Vetter staff. The project itself is considered innovative, as is the employment of the user-centered method ‘Design Thinking’. Following the June kick-off workshop, participants entered into dialogue with the users of injectables, in particular, caregivers and patients. With the help of this first-hand knowledge, the teams first designed initial idea concepts and prototypes for discussion and testing among potential users. Further development followed. On September 25, the four groups presented their ideas in short presentations at the company’s Ravensburg Vetter West site. The jury deciding the final winner consisted of Prof. Dr. med. habil. Folker Wenzel, a practicing physician and academic dean for technical physicians at the HFU Furtwangen, Eva-Maria Makutzik, an innovation manager at EIT Health Germany, complemented by senior management representatives of the organizing company Vetter.

“As a leading Contract Development and Manufacturing Organization that teams up with our globally active pharma and biotech customers, we want to bring the needs of users into even greater focus for future activities. Only through this action can we provide patients around the world, in alliance with our customers, with even better and more up-to-date services related to the delivery of injectables,” said Dr. Claus Feussner, Senior Vice President Vetter Development Service. “The format of the Open Innovation Challenge – Injection 2.0, which targets new approaches in injectable delivery, was an overall success. We were impressed not only with the results of the participating teams, but also their general approach and team spirit created during the challenge.”

These positive outcomes are the reasons why Vetter is considering the establishment of such formats, in addition to its proven processes. In this way, the company strives to promote and advance its innovation capabilities. Through the application of these measures, the CDMO significantly contributes to the preservation of quality of life for patients, both today and into the future.

Participant Tobias Schloegl, a project manager with responsibilities for realizing development projects of pharma and biotech customers within Vetter, also expressed his satisfaction for the challenge. “Joining the Vetter Open Innovation Challenge was a great experience. By doing so, we had the significant opportunity of developing, testing and implementing our own ideas in close consultation with subject matter experts as well as the end-users themselves. This was an exciting and demanding challenge for everyone involved, and one which only a few companies are able to offer.”

Find the Vetter press kit, additional press releases, high-resolution pictures and more background information in our Download Center.

About Vetter

Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. Currently employing 4,400 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180926005504/en/